Summary
In insulin-dependent diabetes mellitus (IDDM), microalbuminuria predicts renal and cardiovascular disease. We report a combined analysis of 235 normotensive IDDM patients with microalbuminuria who participated in two 24-month double-blind, randomised, placebo-controlled trials to assess the effects of captopril 50 mg twice daily on the progression to overt clinical albuminuria. Of the 225 patients who were evaluable on an intent to treat basis, 25 of 114 placebo-treated patients (21.9%) and 8 of 111 captopril-treated patients (7.2%) progressed to persistent clinical albuminuria. The risk of progression over 24 months was significantly reduced by captopril (p=0.004) with a risk reduction of 69.2% (95% confidence interval (CI): 31.7 to 86.1%). This degree of risk reduction remained at the same level (62.9% [16.1–83.6%], p=0.017) after adjustment for differences in time-varying mean arterial blood pressure. Albumin excretion rate increased by an average of 14.2% [3.1–26.5%] per year in the placebo-treated group compared with a reduction of 9.6% [−18.6–0.4%] per year in the captopril-treated group (p=0.002). The rate of fall of creatinine clearance tended to be faster in the placebo-treated group than in the captopril-treated group (−6.4 [−10.2–−2.5] vs −1.4 [−5.3–2.6] ml · min−1 · 1.73 m−2, p=0.07). Baseline albumin excretion rate (p<0.0001) and glycated haemoglobin (p=0.03) were independent predictors of progression to clinical albuminuria and changes in mean arterial blood pressure (p=0.02) and serum cholesterol level (p=0.003) were significantly associated with percentage changes in albumin excretion rate. Captopril reduces the risk of progression to overt nephropathy in IDDM patients with microalbuminuria, an effect partly independent of its blood pressure-lowering effects.
Similar content being viewed by others
Abbreviations
- ACE:
-
Angiotensin converting enzyme
- IDDM:
-
insulin-dependent diabetes mellitus
- GFR:
-
glomerular filtration rate
- C:
-
captopril
- P:
-
placebo
- AER:
-
albumin excretion rate
- MAP:
-
mean arterial pressure
References
Mogensen CE (1982) Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 285: 685–689
Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA (1987) Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 294: 1443–1447
Parving HH, Hommel E, Smidt UM (1988) Protection of kidney function and decrease in albuminuria by captopril in insulin-dependent diabetics with nephropathy. BMJ 297: 1086–1091
Parving HH, Hommel E, Nielsen MD, Giese J (1989) Effect of captopril on blood pressure and kidney function in normotensive insulin-dependent diabetics with nephropathy. BMJ 299: 533–536
Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM (1986) Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925–1930
Anderson S, Rennke HG, Garcia DL, Brenner BM (1989) Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 36: 526–536
Bjorck S, Mulec H, Johnsen SA, Nordén G, Aurell M (1992) Renal protective effect of enalapril in diabetic nephropathy. BMJ 304: 339–343
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456–1462
Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H (1982) Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet i:1430–1432
Parving HH, Oxenboll B, Svendsen PA, Christiansen JS, Andersen AR (1982) Early detection of patients at risk of developing diabetic nephropathy: a longitudinal study of urinary albumin excretion. Acta Endocrinol (Copenh) 100: 550–555
Mogensen CE, Christensen CK (1984) Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311: 89–93
Mathiesen ER, Oxenboll B, Johansen K, Svendsen PA, Deckert T (1984) Incipient nephropathy in type 1 (insulin-dependent) diabetes. Diabetologia 26: 406–410
Messent JWC, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC (1992) Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus. Kidney Int 41: 836–839
Marre M, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P (1988) Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 297: 1092–1095
Melbourne Diabetic Nephropathy Study Group (1991) Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 302: 210–216
Hallab M, Gallois Y, Chatellier G, Rohmer V, Fressinaud P, Marre M (1993) Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin-dependent diabetes. BMJ 306: 175–182
Mathiesen ER, Hommel E, Giese J, Parving HH (1991) Efficacy of captopril in postponing nephropathy in normotensive insulin-dependent diabetic patients with microalbuminuria. BMJ 303: 81–87
Viberti GC, Mogensen CE, Groop LC, Pauls JF, for the European Microalbuminuria Captopril Study Group (1994) Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 271: 275–279
Laffel L, Gans DJ, McGill JB, on behalf of the Captopril Nephropathy Study Group (1993) Captopril decreases the rate of progression of renal disease in normotensive, insulin-dependent diabetes mellitus (IDDM) patients with microalbuminuria. J Am Soc Nephrol 4: 304 (Abstract)
Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE (1993) Is screening and intervention for microalbuminuria worthwhile in patients with insulin-dependent diabetes? BMJ 306: 1722–1725
Kearney EM, Mount JN, Watts GF, Slavin BM, Kind PRN (1987) Simple immunoturbidimetric method for determining urinary albumin at low concentrations using Cobas-Bio centrifugal analyzer. J Clin Pathol 40: 465–468
Stein EA (1986) Lipids, lipoproteins and apolipoproteins. In: Tietz NW (ed) Textbook of clinical chemistry. WB Saunders, Philadelphia, pp 829–900
SAS Institute Inc (1991) SAS Technical Report p 217 “SAS/STAT Software: the PHREG Procedure, Version 6”, SAS Institute Inc, Cary, NC
SAS Institute Inc (1990) SAS/STAT user's guide, Version 6, 4th edn, SAS Institute, Cary, NC
SAS Institute Inc (1992) The MIXED Procedure. In: SAS Technical Report p 229, “SAS/STAT Software: Changes and Enchancements, Release 6.07”. SAS Institute Inc, Cary, NC, pp 287–366
Wiedmann P, Boehlen LM, de Courten M (1993) Effects of different antihypertensive drugs on human diabetic proteinuria. Nephrol Dial Transplant 8: 582–584
Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF (1993) Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Int Med 118: 129–138
Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M (1993) Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Int Med 118: 577–581
Rossing P, Hommel E, Smidt UM, Parving HH (1994) Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 45:S145-S149
Apperloo AJ, De Zeeuw D, De Jong PE (1994) Short-term anti-proteinuric response to anti-hypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 45:S174-S178
Williams JD, Coles GA (1994) Proteinuria — a direct cause of renal morbidity. Kidney Int 45: 443–450
Microalbuminuria Collaborative Study Group, UK (1993) Risk factors for the development of microalbuminuria in insulin dependent diabetic patients: a cohort study. BMJ 306: 1235–1239
Krolewski AS, Warram JH, Christlieb AR (1994) Hypercholesterolemia — a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int 45:S125-S131
Feldt-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, Deckert T (1991) Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. Diabetologia 34: 164–170
The Diabetes Control and Complications Trial Research Group (1993) The effects of intensive treatment of diabetes on the development of long-term complications in insulin-dependent diabetes. N Engl J Med 329: 977–986
Poulsen PL, Hansen KW, Mogensen CE (1994) Ambulatory blood pressure monitoring in the transition from normo- to microalbuminuria. Diabetes 43: 1248–1253
Anderson S, Meyer T, Rennke HG, Brenner BM (1985) Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76: 612–619
Raij L, Keane WF (1985) Glomerular mesangium: its function and relationship to angiotensin II. Am J Med 79[Suppl C]: 24–30
Yoshida Y, Kawamura T, Ikoma M, Fogo A, Ichikawa I (1989) Effects of antihypertensive drugs on glomerular morphology. Kidney Int 36: 626–635
Raij L, Luscher TF, Vanhoutte PM (1988) High potassium diet augments endothelium-dependent relaxations in the Dahl rat. Hypertension 12: 562–567
The Microalbuminuria Collaborative Study Group, UK (1995) Intensive therapy and progression to clinical albuminuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. BMJ 311: 973–977
Diabetes Control and Complications (DCCT) Research Group (1995) Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 42: 1703–1720
Siegel JE, Krolewski AS, Warram JH, Weinstein WC (1992) Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J Am Soc Nephrol 3: 3111–3119
Robdy R, Firth L, Lewis E (1994) An economic analysis of captopril in the treatment of diabetic nephropathy. J Am Soc Nephrol 5: 382 (Abstract)
Author information
Consortia
Additional information
Corresponding author: Professor G.C. Viberti, Unit for Metabolic Medicine, United Medical and Dental Schools of Guy's and St. Thomas' Hospitals, Guy's Hospital, London SE1 9RT, UK
Membership of the Study Group is listed in the Acknowledgement section
Rights and permissions
About this article
Cite this article
The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 39, 587–593 (1996). https://doi.org/10.1007/BF00403306
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00403306